October 30th 2024
A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.
October 16th 2024
Study featured at ASTRO 2024 is one of the first to assess single-fraction SBRT for centrally located lung cancers
October 11th 2024
Roswell Park’s Dr. Eunice Wang led KOMET-001 clinical trial; results newly reported in The Lancet Oncology.
October 1st 2024
September 24th 2024
Black patients and older adults are least likely to undergo this treatment for blood cancers and hematologic disorders.
August 30th 2024
Third year in a row cancer center has been ranked on this listing, based on employee surveys.
August 23rd 2024
A study demonstrates that adding a JAK2 inhibitor to standard immunosuppressive drugs does not improve prevention of acute graft-versus-host disease.
August 14th 2024
A study led by experts at Roswell Park Comprehensive Cancer Center suggests that e-cigarette use may help some people quit using combustible cigarettes.
July 11th 2024
Research team shares new data on how XPO1 blockade may boost immune-based treatments.
July 8th 2024
Using multiomics, the team identifies novel therapeutic targets in castration-resistant prostate cancer.
July 4th 2024
Roswell Park Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
June 16th 2024
Roswell Park researchers and partners shed light on how body composition at the time of diagnosis relates to mortality in epithelial ovarian cancer.
June 10th 2024
To improve access to lung cancer screening, Roswell Park Comprehensive Cancer Center experts have launched an online provider registry.
June 8th 2024
Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.
June 4th 2024
Sai Yendamuri, MD, MBA, FACS, has been appointed as Chief Strategy Officer and Senior Vice President of Business Development and Outreach.
May 23rd 2024
Roswell Park Comprehensive Cancer Center earned top score of 100 on Human Rights Campaign Foundation survey.
November 8th 2022
A targeted therapy for children with high-risk Hodgkin lymphoma was shown to significantly reduce relapse rates when tested in a clinical trial conducted by the Children’s Oncology Group and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children’s Healthcare of Atlanta and Winship Cancer Institute of Emory University.